# EDGAR Filing Document

**Accession Number:** 0001015820
**File Stem:** 0001015820-26-000020
**Filing Date:** 2026-3
**Character Count:** 2177
**Document Hash:** 9818daae8d65a0fae1ee301a35630632
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001015820-26-000020.hdr.sgml**: 20260320

**ACCESSION NUMBER**: 0001015820-26-000020

**CONFORMED SUBMISSION TYPE**: IRANNOTICE

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260320

**DATE AS OF CHANGE**: 20260319

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** QIAGEN N.V.
- **CENTRAL INDEX KEY:** 0001015820
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** IRANNOTICE
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38332
- **FILM NUMBER:** 26775916

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** HULSTERWEG 82
- **CITY:** PL VENLO
- **NON US STATE TERRITORY:** NETHERLANDS
- **PROVINCE COUNTRY:** P7
- **ZIP:** 5912 PL
- **BUSINESS PHONE:** 31-77-35566-00

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** HULSTERWEG 82
- **CITY:** PL VENLO
- **NON US STATE TERRITORY:** NETHERLANDS
- **PROVINCE COUNTRY:** P7
- **ZIP:** 5912 PL

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** QIAGEN NV
- **DATE OF NAME CHANGE:** 19960531

![qiagen_logoa.jpg](qiagen_logoa.jpg)

QIAGEN N.V.

Hulsterweg 82

5912 PL Venlo

The Netherlands

March 19, 2026

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

Re: Notice of Disclosure Filed in Exchange Act Annual Report Under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act

Ladies and Gentlemen:

Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that QIAGEN N.V. has made disclosure pursuant to such provisions in its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, which was filed with the U.S. Securities and Exchange Commission on March 19, 2026.

Sincerely,

---

| |
|:---|
| /s/ Roland Sackers |
| Roland Sackers |
| Chief Financial Officer |

---

<br>